Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a sell rating to a hold rating in a research report sent to investors on Thursday.

Other research analysts have also issued reports about the stock. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. HC Wainwright restated a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a report on Wednesday, March 19th. Finally, Royal Bank of Canada reduced their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a report on Wednesday, March 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Inovio Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $12.20.

Inovio Pharmaceuticals Price Performance

Inovio Pharmaceuticals stock opened at $1.74 on Thursday. The stock’s 50 day moving average price is $1.87 and its 200 day moving average price is $3.00. Inovio Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $13.44. The company has a market cap of $63.80 million, a PE ratio of -0.44 and a beta of 1.84.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.18. The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.03 million. On average, equities research analysts anticipate that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Alpine Global Management LLC acquired a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $31,000. BNP Paribas Financial Markets boosted its holdings in shares of Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 3,630 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Inovio Pharmaceuticals in the fourth quarter valued at $43,000. Boothbay Fund Management LLC acquired a new position in Inovio Pharmaceuticals in the fourth quarter valued at $44,000. Finally, Barclays PLC lifted its position in Inovio Pharmaceuticals by 15.0% during the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 5,111 shares during the period. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.